CurrentEndo
Get Weekly

Stay current with endocrinology research.

Structured Briefs, a personalized Weekly, and a searchable archive of clinically relevant studies from leading journals.

Free34 journals17,493 BriefsFounded by a cardiovascular researcher, MD

Personalized updatesFollow what interests youChoose your topics, journals and study designs. See matching new studies in My Week, or receive them in a personalized weekly e-mail.Choose what to follow Searchable archiveFind relevant researchStructured endocrinology Briefs from leading journals. Search by keyword or filter by topic, study design, journal and date.Explore the archive
Read the full issue

Week 46 · studies published 9–15 November 2026

  1. The Lancet

    Randomized controlled trialObesity

    Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial

    pooled survodutide compared with placebo

    Primary result

    HR 0.8995% CI 0.67–1.18 · P < 0.0001 for non-inferiority

    SURVODUTIDE (POOLED)vs PLACEBO
    HR 0.89 (95% CI 0.67–1.18); P < 0.0001 for non-inferiority

    Read the Brief

  2. JAMA

    Randomized controlled trialObesity

    Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA)

    Orforglipron vs placebo

    Change in apnea-hypopnea index (AHI, events/h) from baseline

    Difference (95% CI)P value
    ORFORGLIPRON (trial 1)vs PLACEBO (trial 1)trial 1
    −13.2(−17.7 to −8.7)
    P < 0.001
    ORFORGLIPRON (trial 2)vs PLACEBO (trial 2)trial 2
    −12.0(−17.1 to −6.9)
    P < 0.001

    Read the Brief

  3. The BMJ

    Randomized controlled trialT2D & other

    Effect of intensive blood pressure control on cognitive outcomes and brain structures in adults with type 2 diabetes: prespecified analysis of secondary outcomes of BPROAD randomised controlled trial

    Intensive treatment targeting systolic blood pressure (SBP) <120 mm Hg vs standard treatment targeting SBP <140 mm Hg for up to five years

    Composite of all cause dementia or mild cognitive impairment

    hazard ratio 0.9695% CI 0.86–1.06 · P = 0.38

    INTENSIVEvs STANDARD
    hazard ratio 0.96 (95% CI 0.86–1.06); P = 0.38

    Read the Brief

Just published

More in Explore